BiotechTube
Frame Bio

Frame Bio

San Francisco, United States· Est.
frame.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Frame Bio is an early-stage biotech (founded 2021) pioneering targeted therapies for bone and connective tissue diseases. Its core technology utilizes a licensed extracellular vesicle (yEV™) delivery system from Mercury Bio to precisely transport molecular payloads like BMP-2 to injured tissues. The company is developing a pre-clinical pipeline aimed at collagen regeneration and bone repair, targeting large, underserved patient populations with chronic structural diseases. Frame Bio operates as a private, pre-revenue entity based in San Francisco.

OsteoporosisConnective Tissue DisordersBone FracturesAutoimmune Diseases

Technology Platform

Licensed extracellular vesicle (yEV™) drug delivery platform from Mercury Bio Inc. for targeted transport of molecular therapeutics (e.g., proteins, RNA) to bone, joint, and collagen-rich tissues. Also exploring combination with hydroxyapatite for bone-specific localization.

Opportunities

The large, underserved patient populations with osteoporosis and connective tissue disorders represent a multi-billion dollar market.
A successful targeted delivery platform could revolutionize treatment from symptom management to true regeneration, offering superior efficacy and safety profiles over current systemic or poorly localized therapies.

Risk Factors

High technical risk associated with developing a novel EV delivery platform, including manufacturing, targeting consistency, and payload efficiency.
Significant financial risk as a pre-revenue startup requiring substantial capital to fund costly clinical development.
Competitive risk from large pharma and other biotechs in regenerative medicine.

Competitive Landscape

Frame Bio competes in the regenerative medicine and targeted drug delivery space. Direct competitors include companies developing improved BMP-2 delivery systems (e.g., with novel scaffolds) and other EV-based therapeutic companies. It also faces indirect competition from large pharma with osteoporosis biologics (e.g., romosozumab) and broad anti-inflammatory therapies.

More companies in Drug Delivery & Formulation →More companies in United States →